The ALK+ ALCL cell lines SUP-M2 and SU-DHL-1, which are highly sensitive to ALK inhibition (Figure 1A), were selected in increasing concentrations of either crizotinib or ceritinib to investigate mechanisms of acquired resistance. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.